Author: admin

Graves Ophthalmopathy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited

The Key Graves Ophthalmopathy Companies in the market include – Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others.

 

The Graves Ophthalmopathy market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Graves Ophthalmopathy pipeline products will significantly revolutionize the Graves Ophthalmopathy market dynamics.

 

DelveInsight’s “Graves Ophthalmopathy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Graves Ophthalmopathy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

To Know in detail about the Graves Ophthalmopathy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Graves Ophthalmopathy Market Forecast

 

Some of the key facts of the Graves Ophthalmopathy Market Report:

  • The Graves Ophthalmopathy market size was valued approximately USD 2600 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In May 2025, Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company dedicated to developing and commercializing potential best-in-class treatments for serious and rare conditions, has announced encouraging long-term durability results from the Phase 3 THRIVE clinical trial of veligrotug (“veli”). Veli is an intravenously administered antibody targeting the insulin-like growth factor-1 receptor (IGF-1R) and is being evaluated in patients with active thyroid eye disease (TED), an autoimmune disorder marked by inflammation, tissue expansion, and damage around and behind the eyes.

  • In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company specializing in the development of oral therapies for thyroid eye disease (TED), has announced topline efficacy and safety results from its Phase 2b/3 LIDS trial evaluating linsitinib in patients with active, moderate to severe TED. Linsitinib, the company’s lead oral small molecule candidate, is administered twice daily and is currently in clinical development for TED. It targets the well-established IGF-1R pathway and has demonstrated a favorable safety profile, having been studied in over 900 patients across fifteen clinical trials in various therapeutic areas.

  • In September 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to discovering and developing potential best-in-class treatments for serious and rare diseases, today announced promising topline results from the THRIVE phase 3 clinical trial of VRDN-001, now known as veligrotug. This intravenously administered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody is being evaluated in patients with active thyroid eye disease (TED), an autoimmune disorder marked by inflammation, growth, and damage to the tissues surrounding and behind the eyes

  • In 2022, approximately 2,385,900 cases of Graves Ophthalmopathy were reported in the seven major markets (7MM), and it is anticipated that these figures will rise throughout the study period from 2020 to 2034.

  • In 2022, it was estimated that there were approximately 448,800 diagnosed prevalent cases of Graves Ophthalmopathy in the United States. It is projected that these cases will increase over the study period from 2020 to 2034.

  • In 2022, Germany had the highest number of diagnosed prevalent cases of Graves Ophthalmopathy patients among the EU4 and the UK, with around 105,900 cases. Conversely, Spain had the fewest cases, with approximately 59,200 cases in 2022.

  • In the United States, the number of diagnosed prevalent cases of Graves Ophthalmopathy was higher among females compared to males in 2022, with approximately 89,800 cases in males and around 359,000 cases in females.

  • Key Graves Ophthalmopathy Companies: Immunovant Sciences GmbH, Horizon Pharma USA, Inc., Viridian Therapeutics, Inc., Tourmaline Bio, Inc., ACELYRIN Inc., Hoffmann-La Roche, Horizon Therapeutics USA, Inc., Lassen Therapeutics Inc., Novartis, Sling Therapeutics, Inc., Lassen Therapeutics, and others

  • Key Graves Ophthalmopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 – 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others

  • The Graves Ophthalmopathy epidemiology based on gender analyzed that the females are affected more as compared to males in the case of Graves Ophthalmopathy

 

Graves Ophthalmopathy Overview

Graves’ ophthalmopathy, also known as thyroid eye disease or Graves’ orbitopathy, is a condition characterized by inflammation and swelling of the tissues surrounding the eyes. It is commonly associated with Graves’ disease, an autoimmune disorder that affects the thyroid gland, leading to hyperthyroidism (overactive thyroid).

 

Get a Free sample for the Graves Ophthalmopathy Market Report –

https://www.delveinsight.com/report-store/graves-ophthalmopathy-market

 

Graves Ophthalmopathy Market

The dynamics of the Graves Ophthalmopathy market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

“The DAVIAD project successfully resulted in the manufacture GMP grade ATX-GD-59 and completion of pharmacodynamic and toxicology studies in order to progress the therapeutic vaccine into a Phase I/IIa clinical trial. In the clinical trial, the vaccine was proven to be safe and well tolerated.”

 

Graves Ophthalmopathy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Graves Ophthalmopathy Epidemiology Segmentation:

The Graves Ophthalmopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Prevalent Cases of Graves Ophthalmopathy in the 7MM

  • Diagnosed Prevalent Cases of Graves Ophthalmopathy in the 7MM

  • Gender-specific Diagnosed Prevalent Cases of Graves Ophthalmopathy in the 7MM

  • Moderate-to-severe Drug-treated Cases of Acute Graves Ophthalmopathy in the 7MM

  • Acute Diagnosed Prevalent Cases of Graves Ophthalmopathy in the 7MM

  • Diagnosed Prevalent Cases of Graves Ophthalmopathy by Chronicity in the 7MM

 

Download the report to understand which factors are driving Graves Ophthalmopathy epidemiology trends @ Graves Ophthalmopathy Epidemiological Insights

 

Graves Ophthalmopathy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Graves Ophthalmopathy market or expected to get launched during the study period. The analysis covers Graves Ophthalmopathy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Graves Ophthalmopathy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Graves Ophthalmopathy Therapies and Key Companies

  • Batoclimab (IMVT 1401): Immunovant Sciences

  • RVT-1401: Immunovant Sciences GmbH

  • Teprotumumab: Horizon Pharma USA, Inc.

  • VRDN-001 10 mg/kg Drug: Viridian Therapeutics, Inc.

  • Batoclimab: Immunovant Sciences GmbH

  • TOUR006 – 20 MG: Tourmaline Bio, Inc.

  • IBI311: Innovent Biologics (Suzhou) Co. Ltd.

  • lonigutamab: ACELYRIN Inc.

  • Satralizumab: Hoffmann-La Roche

  • TEPEZZA: Horizon Therapeutics USA, Inc.

  • LASN01: Lassen Therapeutics Inc.

  • CFZ533: Novartis

  • linsitinib: Sling Therapeutics, Inc.

  • LASN01: Lassen Therapeutics

 

To know more about Graves Ophthalmopathy treatment, visit @ Graves Ophthalmopathy Medications

 

Graves Ophthalmopathy Market Strengths

  • The recent US FDA approval of Horizon’s TEPEZZA has accelerated the research and development of GO.

  • Recent efforts to increase patient and clinician awareness of GO, with various awareness campaigns, are expected to increase early diagnosis and treatment of GO.

 

Graves Ophthalmopathy Market opportunities

  • Designing an effective molecule with an intended delivery mode that is matched to the intended target compartment is a necessary first step in ocular drug discovery programs.

  • Lack of availability of disease-modifying treatment for chronic patients, who have a significant impact on their emotional and social well-being.

 

Scope of the Graves Ophthalmopathy Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Graves Ophthalmopathy Companies: Novartis, AdvanceCor, Apitope, Worg Pharmaceuticals, AV7 Limited, and others

  • Key Graves Ophthalmopathy Therapies: Batoclimab (IMVT 1401), RVT-1401, Teprotumumab, VRDN-001 10 mg/kg Drug, TOUR006 – 20 MG, IBI311, lonigutamab, Satralizumab, TEPEZZA, LASN01, CFZ533, linsitinib, LASN01, and others

  • Graves Ophthalmopathy Therapeutic Assessment: Graves Ophthalmopathy current marketed and Graves Ophthalmopathy emerging therapies

  • Graves Ophthalmopathy Market Dynamics: Graves Ophthalmopathy market drivers and Graves Ophthalmopathy market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Graves Ophthalmopathy Unmet Needs, KOL’s views, Analyst’s views, Graves Ophthalmopathy Market Access and Reimbursement

 

Discover more about therapies set to grab major Graves Ophthalmopathy market share @ Graves Ophthalmopathy Treatment Landscape

 

Table of Contents

1. Graves Ophthalmopathy Market Report Introduction

2. Executive Summary for Graves Ophthalmopathy

3. SWOT analysis of Graves Ophthalmopathy

4. Graves Ophthalmopathy Patient Share (%) Overview at a Glance

5. Graves Ophthalmopathy Market Overview at a Glance

6. Graves Ophthalmopathy Disease Background and Overview

7. Graves Ophthalmopathy Epidemiology and Patient Population

8. Country-Specific Patient Population of Graves Ophthalmopathy

9. Graves Ophthalmopathy Current Treatment and Medical Practices

10. Graves Ophthalmopathy Unmet Needs

11. Graves Ophthalmopathy Emerging Therapies

12. Graves Ophthalmopathy Market Outlook

13. Country-Wise Graves Ophthalmopathy Market Analysis (2020–2034)

14. Graves Ophthalmopathy Market Access and Reimbursement of Therapies

15. Graves Ophthalmopathy Market Drivers

16. Graves Ophthalmopathy Market Barriers

17. Graves Ophthalmopathy Appendix

18. Graves Ophthalmopathy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Graves Ophthalmopathy Market Set to Grow Substantially Through 2034, DelveInsight Projects | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited

Productivity Point Announces Three New Courses for Leadership Development

Productivity Point Announces Three New Courses for Leadership Development
Courses focus on cultural intelligence, leadership competencies, and mastering management skills.

Productivity Point has introduced three new courses designed to help professionals lead more effectively and work more efficiently in a rapidly evolving business landscape.

Sharpen Your Leader Edge: Competencies for the Modern Leader is a two-day course focused on behaviors that distinguish great leaders. It covers ethical leadership, applying different types of leadership power, leading by example, and crafting a compelling vision. Participants will examine nine leadership competencies–including integrity, passion, creativity, and humor–that go beyond traditional management theory. The course includes exercises tied to real leadership challenges and a model for identifying strengths and growth areas. Available online and in person in Los Angeles, CA.

Mastering Management Skills with Influence and Impact is a two-day foundational course that equips managers with practical strategies for leading teams effectively and addressing challenges early. Participants will sharpen communication skills, build high-performing teams, and learn to delegate and coach for better results. Emphasis is placed on understanding team roles, resolving conflicts positively, and applying structured problem-solving methods to drive success.

Driving Results: Leading and Inspiring VirtualTeams is designed to support today’s remote workplace. This one-day course helps managers build trust, improve communication, and keep virtual teams aligned. Through interactive modules, participants learn to identify the right tools, recognize unproductive behaviors, and implement best practices. The course prepares leaders to overcome distance-related challenges while creating a cohesive, high-performing virtual team.

The Culturally Intelligent Leader explores how leaders can work effectively across cultures, emphasizing self-awareness, adaptability, and inclusive decision-making. It’s designed to equip participants with frameworks and tools that help them navigate today’s global and diverse workforce challenges. Available online soon!

About Productivity Point

Productivity Point delivers interactive training, blending technical and professional development with real-world application. The organization’s adult learning model emphasizes hands-on engagement, immediate relevance, and practical problem-solving. Led by experienced professionals, Productivity Point equips learners with tools that directly support organizational performance and individual growth.

Media Contact
Company Name: Productivity Point Learning Solutions
Contact Person: Nichole St. Hilaire
Email: Send Email
Phone: 844-238-8607
Address:1580 Sawgrass Corporate Parkway Suite 205
City: Sunrise
State: Florida 33323
Country: United States
Website: https://www.productivitypointls.com/

Credit Absolute Builds Ethical Partnership Networks for Credit Repair Success in 2025

Credit Absolute Builds Ethical Partnership Networks for Credit Repair Success in 2025

Credit Absolute, a faith-driven leader in credit repair, is revolutionizing the industry with ethical partnership networks that empower individuals and couples (ages 25-60) to achieve financial freedom. In a $5.29 billion credit repair market growing at 13.33% annually, Credit Absolute’s transparent, FCRA-compliant approach connects realtors, loan officers, and legal firms to deliver holistic solutions, turning renters into homeowners and rebuilding trust in a scam-prone industry.

Why Partner with Credit Absolute?

  • Faith-Based Ethos: Partnerships rooted in integrity, like with AZ Notary Solutions and McCarthy Law, ensure client-first outcomes.
  • LevelUp Integration: Real-time Credit Action Plans provide partners with reliable tools for client progress tracking.
  • Affiliate Program: Earn rewards via affiliate.creditabsolute.com/referral-submit while receiving mortgage-ready leads for mutual growth.
  • Free Tools: 30+ credit tips and video testimonials inspire clients with 100+ point score boosts.
  • Lifetime Membership: Pay-only-for-results model with lifelong coaching ensures lasting success.

“Together, we empower with purpose,” says Derick Vogel, Founder & CEO. “Our partners help clients overcome denials for loans or credit cards, building a stronger future.”

Realtors and loan officers rely on our Credit Action Plan to qualify clients, while smaller firms struggling with FCRA compliance partner with us to leverage LevelUp’s AI-driven tools, outpacing competitors.

Get Involved: Start with a free Credit Action Plan at lending.creditabsolute.com or join our affiliate program today.

About Credit Absolute:

Founded by Derick Vogel, Credit Absolute offers ethical credit repair and funding solutions with a fun, approachable style. With over a decade of experience, we empower clients and partners nationwide through education, transparency, and faith-driven innovation.

Media Contact
Company Name: Credit Absolute
Contact Person: Derick Vogel, CEO
Email: Send Email
Phone: 480-906-3777
City: Gilbert
State: AZ
Country: United States
Website: https://www.creditabsolute.com/

GSL ENERGY: 3 Key Principles to Seize the Global C&I Energy Storage Opportunity

The Data shows that global new installations of industrial and commercial (C&I) energy storage reached 4.4 GW/10.9 GWh in 2024, marking a 44.6% year-on-year increase in capacity. It is projected that global new installations will reach 6.1 GW/15.26 GWh in 2025, reflecting a 40% year-on-year growth.

High demand drives rapid growth, but it also presents challenges such as safety and localized global delivery services. At this critical juncture of industry development, Shenzhen GSL ENERGY Co., Ltd. (hereinafter referred to as “GSL ENERGY”) has firmly seized the global C&I energy storage opportunity by leveraging its 15 years of experience in energy storage, a comprehensive product portfolio, and global service capabilities.

1. C&I Energy Storage Requires Safe and Stable Integration Technology

The integrated technology solution for C&I energy storage is a crucial component of the new energy sector, encompassing battery storage systems, energy management systems (EMS), and system integration, with battery storage technology at its core.

As a 15-year veteran in the battery storage field, GSL ENERGY founder, Jim Deng, led the team to develop a Battery Management System (BMS) as early as 2011, which gained market recognition.

In 2024, the global C&I energy storage market reached a scale of $51.1 billion. Energy storage cabinets are widely used in power load management, microgrids, emergency power supplies, and energy optimization. However, limitations in energy density, charge/discharge efficiency, safety, and lifespan have hindered the large-scale application of energy storage projects.

To address these industry pain points, GSL ENERGY optimized lithium iron phosphate (LFP) batteries with ABS casings, extending battery lifespan by 10%. Later, it developed a patented intelligent BMS that supports high-current fast charging and discharging.

In 2021, GSL ENERGY obtained seven utility model patents for energy storage battery technologies, including shock absorption, heat dissipation, leak detection, and safety explosion-proofing. Unlike other integrators focused on rapid shipments, GSL ENERGY prioritizes the full lifecycle economic benefits of its energy storage cabinets for customers.

They have consistently opted for CATL, EVE, and REPT, the world’s top three Grade A lithium iron phosphate battery cells for PACK integration. Additionally, they incorporate a self-developed BMS with intelligent control to optimize charging and discharging strategies, thereby reducing capacity loss and preventing thermal runaway to ensure safety.

In 2023, to expand production capacity, GSL ENERGY invested in a 15,000㎡ energy storage battery factory in Huizhou, China.

The factory operates under a robust ISO quality management system, with dedicated sections for material storage, debugging, and temperature-controlled testing. It implements 100% full inspection for aging and communication tests, while critical processes such as cell sorting and installation follow strict SOP (Standard Operating Procedure) workflows, including cell selection testing and voltage balancing, to prevent safety incidents at the source.

In October 2024, GSL ENERGY delivered 100 sets of 50kW/100kWh small C&I energy storage systems to schools in Malaysia, earning high praise for product quality and technical service.

2. Diverse Product Portfolio to Meet Flexible Power Consumption in Various Scenarios

The surge in the C&I energy storage market is not only reflected in scale growth but also in diversified demand .

To meet the differentiated requirements of domestic and international markets for battery storage and energy storage systems,GSL ENERGY adopts a multi-category product strategy, flexibly addressing diverse power consumption needs.

GSL ENERGY LFP batteries, with capacities ranging from a few kilowatts to several megawatts, covering low-, medium-, and high-voltage for both home and industrial storage scenarios. It provides tailored energy storage solutions for different power consumption patterns.

For instance, in response to the intermittency and volatility risks in Europe’s energy transition, GSL ENERGY has identified high-energy-density, easy-to-install solar-storage integrated systems as a promising growth area.

In March 2025, GSL ENERGY installed 200 sets of 80kW/172kWh liquid-cooled energy storage cabinets for a factory in Ukraine. With 8,500 battery cycles and a 90% depth of discharge (DOD), the system is projected to generate $1.64 million in annual net revenue, with a subsidized payback period of 3.4 years and an IRR exceeding 18%.

For the Middle East’s high-temperature, arid environment, GSL ENERGY focused on lower cost .

On December 30, 2024, GSL ENERGY successfully implemented a 4.6MWh liquid-cooled energy storage project in the Middle East. The system, housed in 20-foot standard containers, achieved a 45% increase in energy density compared to the previous generation. The modular design saved 20% floor space, while optimized liquid-cooling pipelines enhanced safety and simplified maintenance, even under extreme heat.

In response to power outages, rising electricity prices, and grid instability in Asia, Africa, and Latin America, GSL ENERGY launched a new 125kW/261kWh C&I energy storage product. It supports flexible parallel expansion from 261kWh to 2.61MWh, with IP65-rated PACK design for easy capacity expansion and seamless on/off-grid switching, reducing initial investment costs. The product is widely used in peak-shaving, backup power, and microgrid applications.

3. Global Demand Surge: Localization and Service Capabilities Are Key

As global demand for C&I energy storage grows, more manufacturers are competing in overseas markets. However, challenges such as timely delivery, technical training, and product certification persist.

In January 2025, at the invitation of a South American government, GSL ENERGY installed 1,000 sets of 70kWh C&I battery storage systems in a remote Amazon jungle within a month, transforming residents daily 2-hour power supply into 24/7 electricity, supported by on-site training and after-sales technical service.

GSL ENERGY founder, Jim Deng, believes that global delivery and localized service capabilities are critical to capitalize on the global energy storage boom.

Thanks to early international trade, GSL ENERGY has established a comprehensive global product certification system for its energy storage solutions, covering regions such as Europe, Latin America, Africa, and Asia. Its 232kWh and 372kWh liquid-cooled energy storage cabinets have obtained UL1973 and UL9540 certifications from Canada and the U.S., making it one of the few manufacturers meeting North America’s high-performance energy storage standards.

By 2025, GSL ENERGY products have been deployed in 138 countries, with after-sales technical service centers in North America, the Middle East, Germany, and other regions.

Media Contact
Company Name: GSL ENERGY
Contact Person: Cirrus
Email: Send Email
Country: China
Website: https://www.gsl-energy.com

$750 Million Ketamine Drug Market, Projected to Reach $3.35 Billion in 2034 Coming Withing Reach via New Commissioner’s National Priority Vouchers with Anticipated Approval by Year-End for: NRXP

$750 Million Ketamine Drug Market, Projected to Reach $3.35 Billion in 2034 Coming Withing Reach via New Commissioner's National Priority Vouchers with Anticipated Approval by Year-End for: NRXP
$NRXP Has $7.8 Million for Clinic Acquisitions and Purchase of Kadima Neuropsychiatry Institute as Treatment Model and Leading Investigative Site for Suicidal Depression / PTSD
  • Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain.
  • Aiming to be the First FDA-Approved Medication to Treat Suicidal Depression
  • Designed to Help Address the Needs of Over 13 Million Americans who Seriously Consider Suicide Each Year (CDC).
  • Applied for New Commissioner’s National Priority Vouchers (CNPV) for NRX-100 With Anticipated Decisions on Drug Approval by Year-End.
  • Application Under CNPV Program is Accretive to Already-Filed Abbreviated New Drug Application With Proprietary Formulation Under Priority Review Request.
  • Abbreviated New Drug Application Filed for Preservative-Free IV Ketamine.
  • Ketamine Market Estimated at $750 Million and Projected to Reach $3.35 Billion Globally in 2034.
  • $7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions with Universal Capital, LLC.
  • Added to Previously Announced Term Sheet with a Strategic Investor, NRXP HOPE Funding of $10.3 Million is Planned in Near Term.
  • Agreement to Purchase Kadima Neuropsychiatry Institute Expected to Serve as Clinical Model for Treatment Offerings Nationwide.
  • Kadima is a Leading Investigative Site for CNS and Psychedelic Research, Having Served as the Lead Site in Nearly All Major Trials in This Space.
  • Dr. David Feifel, Nationally Recognized Pioneer in Interventional Psychiatry to join as Chief Medical Innovation Officer.
  • New Drug Application for Treatment of Suicidal Depression; Planned NDA for Accelerated Approval for Bipolar Depression in People at Risk of Akathisia.
  • Accepted Non-Binding Potential Terms to License and Distribute NRX-100 Drug Providing Over $300 Million in Milestones Plus Tiered Double-Digit Royalties.
  • Application to Uplist to NASDAQ Global Market from NASDAQ Capital Market.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain

NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.

NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.

Intravenous ketamine is widely accepted as a standard of care for acute treatment of suicidal depression, in the absence of an FDA-labeled product; the only treatment currently approved by the FDA is electroconvulsive therapy (ECT). According to the CDC, 3.8 million Americans make a plan for suicide each year.

Filing of Commissioner’s National Priority Voucher Application for Intravenous Ketamine (NRX-100)

On June 23rd NRXP announced filing for the newly-announced FDA Commissioner’s National Priority Voucher program on behalf of NRX-100, its patent-pending, preservative-free formulation of ketamine for intravenous use.

On June 17, 2025, FDA Commissioner Marty Makary, MD, MPH announced a new approval pathway, the Commissioner’s National Priority Voucher (CPNV)1, for approval of drugs to enhance the health interests of Americans. Previously, on May 25 he identified psychedelic drugs for treatment of suicidal depression and PTSD as a national priority.2 The new voucher may be redeemed by drug developers to participate in a Commissioner-led program that shortens its review time from approximately 10-12 months to 1-2 months following a sponsor’s final drug application submission.

To qualify for the CNPV, sponsors must submit the chemistry, manufacturing, controls (CMC) portion of the application and the draft labeling at least 60 days before submitting the final application. NRXP has already submitted the CMC portion for NRX-100 and received FDA feedback.

Concurrent with the CNPV process, NRXP is preparing a citizen petition to seek withdrawal of preservative-containing forms of ketamine, based on the toxicity associated with the benzethonium chloride preservative used in the historic formulation. NRXP has also filed a patent on its preservative-free manufacturing process. Approval of either the citizen petition, or the patent, would be expected to enable NRXP to gain market share in the current $750 million generic ketamine market that is forecast to reach $3-5 billion annually by 2033, in addition to a share of the market already established for ketamine products for treating depression.

Strategic Investor Relations Partnership with astr partners

On June 16th NRXP announced a strategic investor relations partnership with astr partners, a boutique investor relations and capital advisory firm focused on the life sciences sector.

astr partners will work with the NRXP and HOPE subsidiary executive teams to execute a comprehensive investor relations program that includes investor targeting, message development, earnings preparation, conference support, and proactive investor engagement.

Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

On June 5th NRXP announced the transmission of its Abbreviated New Drug Application (ANDA) for electronic filing to the U.S. Food and Drug Administration (FDA) for NRX-100, its preservative-free IV ketamine formulation, for use in all existing approved indications such as anesthesia and pain management.

NRXP anticipates filing a citizen’s petition with the FDA to remove benzethonium chloride, a known neurotoxic and cytotoxic substance, from presentations of ketamine intended for intravenous use. NRXP believes that the preservative-free feature of NRX-100 will be deemed of benefit to patients because of the known toxicity of closely related benzalkonium chloride in current drug products. Preservatives were originally added to sterile injectable products in an era when a single vial of medication was used to treat multiple patients, a practice no longer allowed in US hospitals. NRXP has demonstrated that there is no need for such preservatives to maintain stability and sterility in ketamine presentations intended for single-patient use. Should the citizen’s petition be granted, all formulations of ketamine sold in the US could face a regulatory requirement to be preservative free.

$7.8 Million Debt Financing to Fuel NRXP HOPE Clinic Acquisitions

On May 15th NRXP announced signing of a term sheet with Universal Capital, LLC to provide $7.8 million in acquisition capital to initiate subsidiary HOPE’s planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital.

HOPE’s three initial acquisitions represent best-in-class clinics that offer neuroplastic treatments including NRXP ketamine and transcranial magnetic stimulation (TMS) to treat patients with severe depression, PTSD, and related central nervous system conditions. Neuroplastic treatments represent a rapidly emerging class of interventions that cause the growth of new connections (synapses) between brain cells that have been shown in multiple clinical trials to relieve symptoms of depression and suicidality. The FDA has approved TMS devices for a number of indications and has approved a nasal form of ketamine for treatment resistant depression. HOPE’s parent company, NRXP, is currently applying to the FDA for approval of intravenous preservative-free ketamine to treat suicidal depression.

Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the NRXP HOPE Network of Interventional Psychiatry Clinics

On May 13th NRXP announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in NRXP HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy.

Kadima is one of California’s flagship interventional psychiatry clinics and was among the first to bring ketamine treatment for central nervous system (CNS) disorders out of academic research settings and into clinical practice. The clinic offers a full range of treatments for suicidal depression, PTSD and other CNS disorders. Further, Kadima and David Feifel, MD PhD, Founder and Medical Director of Kadima, have served as leaders in clinical trial work on emerging therapies in CNS for top companies in the industry. Importantly, the clinic is profitable and is forecast to continue growth going forward. Dr. Feifel will join NRXP HOPE as its first Chief Medical Innovation Officer upon closing of the acquisition.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website

Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: Send Email
Phone: 484 254 6134
Address:1201 Orange Street Suite 600
City: Miami
State: Florida
Country: United States
Website: https://www.nrxpharma.com/

The Knife That Hides Its Clip: Peak Spec’s Sleek New EDC Tool Launches on Kickstarter

MIAMI, FL – June 24, 2025 – After 18 months of development and three successful Kickstarter campaigns, Peak Spec is back with its most innovative product yet: Apex with GHOSTCLIP™, a modern everyday carry knife with a retractable locking pocket clip. The project is now live on Kickstarter and has already begun gaining traction among EDC enthusiasts, knife collectors, and design lovers alike.

Traditional pocket clips are notorious for causing discomfort, snagging on fabric, and scratching gear. GHOSTCLIP™ solves this with a patent-pending HideAway Clip that disappears into the handle when not in use, offering a cleaner grip, snag-free pocket carry, and zero pressure points.

“We didn’t just want to make a better clip—we wanted to reimagine how knives carry, feel, and function,” says Soju A., founder of Peak Spec. “We created GHOSTCLIP™ because we were tired of the downsides of traditional pocket clips—snagging, scratching, and added bulk—but still valued their utility. GHOSTCLIP™ bridges that gap. It’s there when you need it, and disappears when you don’t.”

Features that Set GHOSTCLIP™ Apart

  • Patent-Pending HideAway Clip – Retracts into the handle for a snag-free, comfortable grip
  • Premium Blade Options – D2 tool steel standard, with M390 “super steel” upgrade available
  • Minimalist Design – Slim, lightweight form built for everyday carry
  • Multi-Function Tooling – Integrated pry edge and flathead driver for added utility
  • Tested for Durability – Clip stress-tested to over 10,000+ retractions


A Track Record of Delivery

Peak Spec is no stranger to the Kickstarter community. Its previous projects—the Featherlite, Dart, and Paramount knives—have shipped to thousands of happy backers worldwide. Survey data from past backers shows over 82% would support future projects, reinforcing the brand’s reputation for quality and innovation.

Support the Campaign / Learn More: https://www.kickstarter.com/projects/peakspec/ghostclip-pocket-knife?ref=6h8nzf

Media Contact
Company Name: Peak Spec
Contact Person: Media Manager
Email: Send Email
Country: United States
Website: https://www.kickstarter.com/projects/peakspec/ghostclip-pocket-knife?ref=6h8nzf

Ontario Airport Car & Sedan Service Announces Brand Update and Service Enhancements

Ontario Airport Car & Sedan Service Announces Brand Update and Service Enhancements

Ontario Airport Car & Sedan Service Logo
Visual refresh and operational improvements aim to support more efficient, reliable ground transportation across Ontario and the Inland Empire.

Montclair, CA – Ontario Airport Car & Sedan Service has introduced a refined brand identity and service updates as part of its continued effort to streamline operations and improve the travel experience for clients utilizing executive and airport transportation services. While the company name remains unchanged, the updates are intended to support better service execution and operational clarity.

Based at 5206 Benito St, Ste 208, Montclair, CA, the company serves Ontario and surrounding areas including Rancho Cucamonga, Chino, Upland, and Fontana. The visual adjustments applied across the website, fleet, and employee uniforms aim to create consistency across client touchpoints and enhance recognizability in high-traffic locations such as Ontario International Airport (ONT).

According to Edward Powers, Owner of Ontario Airport Car & Sedan Service, “The visual updates are not just cosmetic. They reflect improvements in workflow, online access, and vehicle coordination, all of which contribute to better service delivery.”

Operational Changes and Their Purpose:

● A redesigned website and online booking platform were introduced to reduce friction during the reservation and dispatch processes.

● Updates to vehicle branding and uniform standards were implemented to aid in quicker identification during pickups and reduce confusion in busy areas.

● The fleet has been expanded to include more executive sedans and SUVs, allowing for greater availability during peak travel hours.

● Service coverage has been clarified and extended in response to demand across key Inland Empire cities.

Elements That Remain Unchanged:

● 24/7 availability supported by licensed, trained chauffeurs

● Standard operating procedures that prioritize punctuality and service consistency

● Adherence to California Public Utilities Commission (CPUC) regulatory requirements

● Use of flight tracking to monitor arrival times and adjust schedules accordingly

The company continues to focus on transportation solutions for business travelers, including airport transfers, client meetings, and corporate events. The recent changes are designed to support these functions with greater reliability and efficiency.

For more information, visit https://ontarioairportcarandsedanservice.com or contact Edward Powers at info@theperfectlimo.com.

Media Contact
Company Name: Ontario Airport Car & Sedan Service
Contact Person: Edward Powers
Email: Send Email
Phone: +1 909?836?1983
Country: United States
Website: https://ontarioairportcarandsedanservice.com/

Systems For Growth Releases its Proven Business Systems Methodology to Global Enterprises

This strategic framework includes consulting, training, and more and has already been implemented to strike success in a long list of early clients

The team at Systems For Growth is thrilled to announce that they are bringing their proven business systems methodology online for the benefit of businesses around the world after much success with pilot clients.

Systems For Growth now has limited availability for clients who are employing 5-50 employees but feel like their growth is stagnant. By using leading-edge strategies and tailor-fit tools, the business growth experts at Systems For Growth have already helped a number of clients reach and exceed their goals. According to pilot clients, the team at Systems For Growth helped their companies achieve dramatically increased profits and a high-performance team in just 12 weeks. This was evidenced by +70% increase in profits; 3x faster growth than competitors; a 15% decrease in operations costs; owners working only 20 hours per week as compared to 60 hours before starting the program; better work environments; a single dashboard for all business operations; and much more.

According to one pilot client, “I’ve loved working with you, you’ve done such a great job. Our business would not still be here if it wasn’t for you. Thank you so much for helping to grow our business.”

Systems For Growth has identified a pattern when it comes to businesses wanting to break through plateaus. Oftentimes, these businesses don’t have dedicated systems in place to help consolidate repetitive tasks or handle team accountability. In addition, there are no decision-making frameworks to streamline operations and empower managers or teams. Owners often feel like they can’t leave or step back because there are no visibility systems or reinforcement loops. Systems For Growth has found that even when these companies are growing, higher profits aren’t necessarily realized.

“At Systems For Growth, our mission is to systemize each client’s business so that it can run without them but also so that it can scale easily,” said a spokesperson for the company. “It’s common that our clients have been saving at least 10 hours a week but also increasing productivity in their enterprise without hiring. They’re seeing up to a 5x ROI, and their teams are operating more efficiently than ever.

While some business owners might feel that they need to completely restructure to achieve success, that’s not usually the case. For instance, the teams that are in place are likely perfectly capable of helping the company see transformational growth, but it could be that they aren’t being utilized properly. That’s where Systems For Growth shines.

The experts at Systems For Growth have shown their track record at leading companies to success even where others have failed. According to the team, many clients have tried coaching and other systems before, but were met with failure or costs that were simply too high. Systems For Growth offers a cost-efficient and highly effective service helps businesses boost their profit margins like nothing else can. This is specifically true for businesses that are beyond startup but stalled in their growth in industries including legal, allied health, clinics, trades, construction firms, manufacturing, real estate, retail, education, coaching, ecommerce, and many others.

“The context may change, but the core challenge remains: you’ve outgrown your current structure, and your team can’t scale without something stronger to support them,” said Ryan Gray at Systems For Growth.

Systems For Growth is championing small to medium sized businesses with a three pillar approach including team alignment, decision-making framework, and process and communication. Right now, prospective clients can sign up for the next limited availability sessions. If they want to see more of what Systems For Growth has to offer, they can enjoy a free download of the Standard Operating Procedure (SOP) Template, a free download that has already been downloaded by many. The SOP Template helps people get the process to help them free up time, systemize teams, and increase profits. This is the same template that Systems For Growth uses to help its clients systemize their businesses quickly, but it’s available for a limited time for free at the Systems For Growth website.

Limited spots are available for the next session of Systems For Growth. Those who enquire now will receive a free consultation to identify their business’s key pain points and potential solutions. Qualified business owners will receive a free consultation to identify their business’s key pain points and possible solutions.

As Systems For Growth brings its proven methodology online, it looks forward to welcoming new business clients aboard. Prospective clients can reserve their spot now by visiting https://systemsforgrowth.co/.

ABOUT SYSTEMS FOR GROWTH

Systems For Growth is a leading-edge business systems coaching and leadership development company offering 12-week group coaching, private consults, video training, and more with an emphasis on fixing systems and profits in record time.

Media Contact
Company Name: Systems For Growth
Contact Person: Ryan Gray
Email: Send Email
City: QUEENSLAND
Country: Australia
Website: https://systemsforgrowth.co/

Hunuu Health Unveils Sensor-based Medical Analytics with AI Outcomes, Revolutionizing Mobile Patient Care

Hunuu Health offers the first integrated health platform linking all aspects of a person’s wellbeing across a single – secure-mobile platform.

Atlanta, GA – June 19th, 2025 – Hunuu Health, a global leader in sensor-based healthcare analytics with AI outcomes, announced the launch of its mobile application on iOS and Google Play stores. Leveraging 5G and sensor technology with state-of-the-art artificial intelligence, Hunuu Health is setting the standard for secure, real-time, personalized, and outcome-driven healthcare at scale. By driving down the costs of patient care, Hunuu reduces the high costs of legacy or outdated CRM systems while delivering efficiencies between patient and provider.

In an increasingly expensive healthcare landscape, Hunuu Health’s innovative mobile platform addresses the critical need for visual real-time patient monitoring, early intervention, and data-driven decision-making. By seamlessly integrating existing health records, hormone levels and lab tests with sensor data, e.g. (smartwatch and sophisticated AI algorithms) the Hunuu Health platform empowers healthcare providers and patients with actionable medical insights across three pillars that include; physical, libido – hormones and emotional health characteristics that lead to significantly improved patient outcomes, reduced readmissions and improved rehabilitation rates at a dramatic cost improvement.

“It’s clear Hunuu’s mission is to empower both patients and healthcare providers the integration they need to deliver the best possible care. With their next-generation sensor-based analytics and AI outcomes, Hunuu is analyzing historical and real-time sensor data; predicting needs, personalizing treatments, and fundamentally changing the trajectory of patient health in a Mobile App, not multi-million-dollar CRMs that still cannot seem to address the need for faxing,” said Kenneth C. Morris, D.C. DACBSP.

Hunuu Health is actively collaborating with leading hospital executives, physio’s, clinics, hormone replacement clinics, research organizations and medical colleges to push the boundaries of integrated sensor-based healthcare. This revolutionary leap sets-free patient data stuck across legacy CRMs, paper files and “supposed” new point solutions that lack end-to-end encryption.

Finally bringing healthcare into 2025, our Hunuu Platform allows patients add DNA, blood tests and MRI scans, from multiple providers, alongside personally generated analytical data to capture a holistic view of their current and future health status. In real-time Doctor’s can analyze real-time graph’s to direct patients’ medical needs. Hunuu AI allows patients to access and securely own all their health data instead of waiting for others to fax or sell your data to advertisers.

Hunuu Health is a family-based, AI privacy first solution now available for immediate implementation and download. For more information, please contact Hunuu PR.

Website: www.hunuuhealth.com

Email: press@hunuuhealth.com

Twitter: @hunuuhealth

Instagram: hunuuhealth

To view original press release on PR Gun, please visit https://prgun.com/press-release/226897/hunuu-health-unveils-sensor-based-medical-analytics-with-ai-outcomes

Media Contact
Company Name: Hunuu Health
Email: Send Email
City: Atlanta
State: GA
Country: United States
Website: https://hunuuhealth.com

Lee Morris, Vice President of Underwriting of Life & Annuity Brokerage with Gallagher, Inc., Interviewed on the Influential Entrepreneurs Podcast

Listen to the interview on the Business Innovators Radio Network: Interview with Lee Morris, Vice President of Underwriting of Life & Annuity Brokerage with Gallagher, Inc.

Lee Morris, Vice President of Underwriting of Life and Annuity Brokerage at Gallagher Incorporated. Lee shares her unique journey into the underwriting field, revealing that few aspire to become underwriters. She began her career at State Farm as a life underwriting management trainee, where she had the opportunity to choose between service and the technical aspects of underwriting. With 34 years of experience, including 17 years at a carrier with significant signing authority, Lee transitioned to the sales side, providing valuable insights into the underwriting process. She discusses her trademarked underwriting training program and her certification in EKG interpretation, highlighting the depth of her expertise in the industry.

The underwriting process in life insurance is often viewed as a rigid and formulaic procedure. However, as discussed in the podcast episode featuring Lee Morris, Vice President of Underwriting at Gallagher Incorporated, it is inherently subjective. This subjectivity stems from various factors, primarily the individual experiences and perspectives of underwriters, which can significantly influence case assessments.

  1. Individual Perspectives: Each underwriter brings their unique experiences to the table. For instance, Lee shared a personal anecdote about her son and ex-husband, both of whom were severe asthmatics. This personal experience shaped her understanding of asthma-related risks differently than what might be indicated in underwriting manuals. Such insights can lead to more favorable assessments for applicants who might otherwise be categorized as high risk based solely on clinical data.
  2. Variability in Assessments: Lee highlighted that even when multiple underwriters review the same case, they may arrive at different conclusions. Lee noted that in underwriting meetings, it was common for ten underwriters to have eight different perceptions of a single risk. This variability underscores the fact that underwriting is not merely a mechanical process; it involves human judgment and interpretation.
  3. Influence of Guidelines: While established guidelines and reinsurance manuals are utilized by most carriers, the interpretation of these guidelines can vary widely among underwriters. Lee pointed out that although carriers may market themselves as having specific advantages for certain medical conditions, many use the same foundational manuals. The subjective nature of underwriting means that one underwriter might view a risk as manageable, while another might see it as too risky, leading to different outcomes for applicants.
  4. Emotional Factors: Underwriters are human and, like anyone else, they can have good and bad days. Lee emphasized that an underwriter’s mood or emotional state can influence their decision-making process. This human element adds another layer of complexity to the underwriting process, potentially leading to inconsistencies in how cases are evaluated.

Gallagher’s underwriting team aims to navigate this subjectivity by providing a comprehensive understanding of the underwriting process. They focus on:

  • Technical Expertise: By leveraging their deep knowledge of medical information and underwriting processes, Gallagher’s team can better advocate for clients and advisors. This expertise allows them to present cases in a way that highlights the nuances and complexities that might otherwise be overlooked.
  • Managing Expectations: Lee emphasized the importance of setting realistic expectations for agents and clients. By explaining the subjective nature of underwriting and the factors that influence assessments, Gallagher helps clients understand potential outcomes and prepares them for the underwriting journey.
  • Advocacy and Partnership: Gallagher positions itself as an extension of the agent’s office, advocating for the client while also protecting the carrier’s interests. This partnership approach fosters a collaborative environment where the goal is to find solutions rather than simply deny cases.

Lee said: “Underwriting subjectivity can create waves for your applicant’s life insurance application, so make sure you have the expertise of Gallagher Underwriting to help navigate you to ‘smooth sailing.”

In conclusion, the underwriting process in life insurance is far from a straightforward, one-size-fits-all procedure. The subjectivity inherent in the process, influenced by individual underwriters’ experiences, perspectives, and emotional states, plays a crucial role in case assessments. Gallagher’s approach to underwriting seeks to navigate these complexities by combining technical expertise with a human touch, ultimately aiming to create win-win scenarios for all parties involved.

Video Link: https://www.youtube.com/embed/e6xkXBH7nNs

About Lee Morris

Lee Morris is Vice President of Underwriting, Life & Annuity Brokerage who rejoined the Gallagher Life & Executive Benefits consulting team in January of 2023.

Lee Morris has been in the insurance industry specializing in technical underwriting risk management for over 33 years. She is known for her astute ability to merge the technical attributes of underwriting with the art of modern-day medical advancements and interpretation while protecting the interests of all stakeholders. Lee’s strong experience with the top one percent of the wealth management firms and the ultra-affluent market demonstrates her ability to address the needs of clients requiring an enhanced “boutique” encounter.

Certified in EKG interpretation and a dynamic presenter, Lee’s past experience of 17 years at the carrier include being Assistant Chief leading one of the top premium distributions in the high-net-worth arena. She is one of very few in the brokerage market who achieved a prior insurance carrier underwriting single signature authority of $20M dollars.

Lee holds a Cum Laude Bachelor of Science Degree in Accounting from Grambling St. University, Grambling, LA. She enjoys her free time volunteering with the K-12 school she is the co-founder of, hunting, shopping and is the mother to one son, Evan who is a Senior Pre-Med student at Morehouse College in Atlanta, Ga.

Learn more: http://www.ajg.com/

Take advantage of the Gallagher Underwriting expertise platform that can move your life insurance consideration from a “success story” to reciprocal “successful solutions” Financial Professionals should ensure they continue to follow the current policies and procedures of their broker dealer and/or registered investment adviser and the insurance carriers they represent on the use of any advertising, third-party materials, sales processes and/or social media/internet use. This marketing presentation in no way supersedes the requirements of a financial professional’s license requirements or the policies and procedures of your broker dealer or registered investment advisory firm. This content is for informational and educational purposes, and is not designed, or intended, to be applicable to any person’s individual circumstances. It should not be considered as investment advice, nor does it constitute a recommendation that anyone engages in (or refrains from) a particular course of action.

Media Contact
Company Name: Marketing Huddle, LLC
Contact Person: Mike Saunders, MBA
Email: Send Email
Phone: 7202323112
Country: United States
Website: https://www.AuthorityPositioningCoach.com